Postpartum Depression: Pathophysiology, Treatment, and Emerging Therapeutics.
allopregnanolone
emerging therapies
genetic aspects
pathophysiology
postpartum depression
Journal
Annual review of medicine
ISSN: 1545-326X
Titre abrégé: Annu Rev Med
Pays: United States
ID NLM: 2985151R
Informations de publication
Date de publication:
27 01 2019
27 01 2019
Historique:
entrez:
30
1
2019
pubmed:
30
1
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
Postpartum depression (PPD) is common, disabling, and treatable. The strongest risk factor is a history of mood or anxiety disorder, especially having active symptoms during pregnancy. As PPD is one of the most common complications of childbirth, it is vital to identify best treatments for optimal maternal, infant, and family outcomes. New understanding of PPD pathophysiology and emerging therapeutics offer the potential for new ways to add to current medications, somatic treatments, and evidence-based psychotherapy. The benefits and potential harms of treatment, including during breastfeeding, are presented.
Identifiants
pubmed: 30691372
doi: 10.1146/annurev-med-041217-011106
doi:
Substances chimiques
Antidepressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM